Biased view of the role of site-specific therapy in carcinoma of unknown primary

Comment

Mary-Elizabeth Percival et al. J Clin Oncol. 2013.

. 2013 Jul 1;31(19):2512-3.

doi: 10.1200/JCO.2013.49.5036. Epub 2013 Jun 3.

No abstract available

Comment in

Reply to M.-E. Percival et al and L.B. Saltz.
Hainsworth JD, Spigel DR, Rubin MS, Boccia RV, Greco FA. Hainsworth JD, et al. J Clin Oncol. 2013 Jul 1;31(19):2514-5. doi: 10.1200/JCO.2013.49.6695. J Clin Oncol. 2013. PMID: 23967489 No abstract available.
Reply to M.-E. Percival et al and L.B. Saltz.
Daud AI. Daud AI. J Clin Oncol. 2013 Jul 1;31(19):2515-6. doi: 10.1200/JCO.2013.49.6703. J Clin Oncol. 2013. PMID: 23967490 No abstract available.

Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.
Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R, Greco FA. Hainsworth JD, et al. J Clin Oncol. 2013 Jan 10;31(2):217-23. doi: 10.1200/JCO.2012.43.3755. Epub 2012 Oct 1. J Clin Oncol. 2013. PMID: 23032625 Clinical Trial.
Removing the unknown from the carcinoma of unknown primary.
Daud AI. Daud AI. J Clin Oncol. 2013 Jan 10;31(2):174-5. doi: 10.1200/JCO.2012.45.7630. Epub 2012 Dec 10. J Clin Oncol. 2013. PMID: 23233703 No abstract available.